|
Sen. Meg Loughran Cappel
Filed: 4/14/2023
| | 10300HB1565sam001 | | LRB103 25816 BMS 60088 a |
|
|
| 1 | | AMENDMENT TO HOUSE BILL 1565
|
| 2 | | AMENDMENT NO. ______. Amend House Bill 1565 by replacing |
| 3 | | line 23 on page 8 through line 11 on page 9 with the following: |
| 4 | | "vaginal estrogen in its formulary. |
| 5 | | (b) If a particular vaginal estrogen product or its |
| 6 | | therapeutic equivalent version approved by the United States |
| 7 | | Food and Drug Administration is determined to be medically |
| 8 | | necessary, the issuer must cover that service or item pursuant |
| 9 | | to the cost-sharing requirement contained in subsection (c). |
| 10 | | (c) A policy subject to this Section shall not impose a |
| 11 | | deductible, copayment, or any other cost sharing requirement |
| 12 | | that exceeds any deductible, coinsurance, copayment, or any |
| 13 | | other cost-sharing requirement imposed on any prescription |
| 14 | | drug authorized for the treatment of erectile dysfunction |
| 15 | | covered by the policy; except that this".
|